Which has stronger valuation & earnings, AMGN or NTRA?

Amgen has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amgen $36.75B 5.95 $7.71B $16.09 25.15 Natera $2.31B 25.59 -$208.16M -$1.36 N/A

Is AMGN or NTRA more profitable?

Amgen has a net margin of 22.95% compared to Natera's net margin of -7.11%. Amgen's return on equity of 124.14% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Amgen 22.95% 124.14% 13.18% Natera -7.11% -11.38% -7.87%

Does the media refer more to AMGN or NTRA?

In the previous week, Amgen had 4 more articles in the media than Natera. MarketBeat recorded 12 mentions for Amgen and 8 mentions for Natera. Natera's average media sentiment score of 0.50 beat Amgen's score of 0.37 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Natera 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, NTRA or GILD?

Gilead Sciences has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 25.59 -$208.16M -$1.36 N/A Gilead Sciences $29.44B 6.11 $8.51B -$2.67 N/A

Is NTRA or GILD more profitable?

Natera has a net margin of -7.11% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.38% -7.87% Gilead Sciences -10.64% -2.11% -0.75%

Does the media favor NTRA or GILD?

In the previous week, Gilead Sciences had 8 more articles in the media than Natera. MarketBeat recorded 16 mentions for Gilead Sciences and 8 mentions for Natera. Gilead Sciences' average media sentiment score of 0.73 beat Natera's score of 0.50 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VRTX or NTRA?

In the previous week, Vertex Pharmaceuticals had 3 more articles in the media than Natera. MarketBeat recorded 11 mentions for Vertex Pharmaceuticals and 8 mentions for Natera. Vertex Pharmaceuticals' average media sentiment score of 0.91 beat Natera's score of 0.50 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Natera 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to REGN or NTRA?

In the previous week, Regeneron Pharmaceuticals had 33 more articles in the media than Natera. MarketBeat recorded 41 mentions for Regeneron Pharmaceuticals and 8 mentions for Natera. Regeneron Pharmaceuticals' average media sentiment score of 0.51 beat Natera's score of 0.50 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 12 Very Positive mention(s) 7 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Natera 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, MRNA or NTRA?

Natera has higher revenue and earnings than Moderna. Natera is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 38.99 -$2.82B -$7.99 N/A Natera $2.31B 25.59 -$208.16M -$1.36 N/A

Is MRNA or NTRA more profitable?

Natera has a net margin of -7.11% compared to Moderna's net margin of -141.43%. Natera's return on equity of -11.38% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Natera -7.11% -11.38% -7.87%

Does the media refer more to MRNA or NTRA?

In the previous week, Moderna had 37 more articles in the media than Natera. MarketBeat recorded 45 mentions for Moderna and 8 mentions for Natera. Natera's average media sentiment score of 0.50 beat Moderna's score of 0.27 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 16 Positive mention(s) 9 Neutral mention(s) 10 Negative mention(s) 0 Very Negative mention(s) Neutral Natera 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Natera (NTRA) Competitors

$410.35 +1.88 (+0.46%)

Closing price 04:00 PM Eastern

Extended Trading

$411.78 +1.43 (+0.35%)

As of 07:55 PM Eastern

Compare

NTRA vs. AMGN, GILD, VRTX, REGN, and MRNA

Should you buy Natera stock or one of its competitors? Natera's main competitors and comparable companies include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Moderna (MRNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Natera compare to Amgen?

Amgen (NASDAQ:AMGN) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Amgen has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	5.95	$7.71B	$16.09	25.15
Natera	$2.31B	25.59	-$208.16M	-$1.36	N/A

Amgen has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Natera has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

Amgen currently has a consensus target price of $385.25, indicating a potential downside of 4.81%. Natera has a consensus target price of $341.55, indicating a potential downside of 16.58%. Given Amgen's higher probable upside, research analysts clearly believe Amgen is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	3 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.33
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Amgen had 4 more articles in the media than Natera. MarketBeat recorded 12 mentions for Amgen and 8 mentions for Natera. Natera's average media sentiment score of 0.50 beat Amgen's score of 0.37 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Natera	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

76.5% of Amgen shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Comparatively, 5.1% of Natera shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Amgen has a net margin of 22.95% compared to Natera's net margin of -7.11%. Amgen's return on equity of 124.14% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	22.95%	124.14%	13.18%
Natera	-7.11%	-11.38%	-7.87%

Summary

Amgen beats Natera on 9 of the 17 factors compared between the two stocks.

How does Natera compare to Gilead Sciences?

Natera (NASDAQ:NTRA) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Gilead Sciences had 8 more articles in the media than Natera. MarketBeat recorded 16 mentions for Gilead Sciences and 8 mentions for Natera. Gilead Sciences' average media sentiment score of 0.73 beat Natera's score of 0.50 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Natera presently has a consensus target price of $341.55, indicating a potential downside of 16.58%. Gilead Sciences has a consensus target price of $158.78, indicating a potential upside of 9.47%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
Gilead Sciences	0 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.79

Natera has a net margin of -7.11% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Gilead Sciences	-10.64%	-2.11%	-0.75%

Gilead Sciences has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	25.59	-$208.16M	-$1.36	N/A
Gilead Sciences	$29.44B	6.11	$8.51B	-$2.67	N/A

99.9% of Natera shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 5.1% of Natera shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Gilead Sciences beats Natera on 9 of the 17 factors compared between the two stocks.

How does Natera compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

In the previous week, Vertex Pharmaceuticals had 3 more articles in the media than Natera. MarketBeat recorded 11 mentions for Vertex Pharmaceuticals and 8 mentions for Natera. Vertex Pharmaceuticals' average media sentiment score of 0.91 beat Natera's score of 0.50 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Natera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Vertex Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	10.64	$3.95B	$17.18	29.30
Natera	$2.31B	25.59	-$208.16M	-$1.36	N/A

Vertex Pharmaceuticals has a net margin of 35.00% compared to Natera's net margin of -7.11%. Vertex Pharmaceuticals' return on equity of 23.09% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.00%	23.09%	16.72%
Natera	-7.11%	-11.38%	-7.87%

Vertex Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Natera has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Vertex Pharmaceuticals currently has a consensus price target of $575.13, indicating a potential upside of 14.26%. Natera has a consensus price target of $341.55, indicating a potential downside of 16.58%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Vertex Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

Vertex Pharmaceuticals beats Natera on 12 of the 17 factors compared between the two stocks.

How does Natera compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Natera's net margin of -7.11%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Natera	-7.11%	-11.38%	-7.87%

Regeneron Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.26	$4.50B	$40.46	18.13
Natera	$2.31B	25.59	-$208.16M	-$1.36	N/A

In the previous week, Regeneron Pharmaceuticals had 33 more articles in the media than Natera. MarketBeat recorded 41 mentions for Regeneron Pharmaceuticals and 8 mentions for Natera. Regeneron Pharmaceuticals' average media sentiment score of 0.51 beat Natera's score of 0.50 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	12 Very Positive mention(s)	7 Positive mention(s)	13 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
Natera	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Natera has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals presently has a consensus price target of $809.50, indicating a potential upside of 10.38%. Natera has a consensus price target of $341.55, indicating a potential downside of 16.58%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.69
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

Regeneron Pharmaceuticals beats Natera on 11 of the 16 factors compared between the two stocks.

How does Natera compare to Moderna?

Moderna (NASDAQ:MRNA) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 5.1% of Natera shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Natera has a net margin of -7.11% compared to Moderna's net margin of -141.43%. Natera's return on equity of -11.38% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Natera	-7.11%	-11.38%	-7.87%

Moderna has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Natera has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

Natera has higher revenue and earnings than Moderna. Natera is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	38.99	-$2.82B	-$7.99	N/A
Natera	$2.31B	25.59	-$208.16M	-$1.36	N/A

In the previous week, Moderna had 37 more articles in the media than Natera. MarketBeat recorded 45 mentions for Moderna and 8 mentions for Natera. Natera's average media sentiment score of 0.50 beat Moderna's score of 0.27 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	9 Very Positive mention(s)	16 Positive mention(s)	9 Neutral mention(s)	10 Negative mention(s)	0 Very Negative mention(s)	Neutral
Natera	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna presently has a consensus price target of $77.83, indicating a potential downside of 59.00%. Natera has a consensus price target of $341.55, indicating a potential downside of 16.58%. Given Natera's stronger consensus rating and higher possible upside, analysts plainly believe Natera is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

Natera beats Moderna on 13 of the 17 factors compared between the two stocks.

Get Natera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTRA vs. The Competition

Export

Metric	Natera	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$58.88B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.77%
P/E Ratio	-301.73	12.93	273.67	26.04
Price / Sales	25.65	1,308.36	612.51	90.64
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	33.15	16.63	10.92	6.30
Net Income	-$208.16M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-0.54%	-3.05%	-2.11%	-1.67%
1 Month Performance	26.20%	-10.75%	-6.34%	-3.94%
1 Year Performance	156.13%	21.11%	8.81%	2.77%

Natera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTRA Natera	2.0808 of 5 stars	$410.35 +0.5%	$341.55 -16.8%	+152.8%	$58.88B	$2.31B	N/A	6,140	Analyst Forecast Insider Trade
AMGN Amgen	3.1931 of 5 stars	$418.13 +0.8%	$385.25 -7.9%	+36.4%	$224.15B	$36.75B	25.99	31,500
GILD Gilead Sciences	4.2487 of 5 stars	$152.21 +0.8%	$158.78 +4.3%	+32.7%	$187.15B	$29.44B	N/A	17,000	Trending News Analyst Downgrade Insider Trade
VRTX Vertex Pharmaceuticals	3.9842 of 5 stars	$527.67 +0.3%	$575.13 +9.0%	+25.4%	$133.55B	$12.00B	30.71	6,400
REGN Regeneron Pharmaceuticals	4.5078 of 5 stars	$752.25 -4.5%	$802.18 +6.6%	+22.5%	$81.13B	$14.34B	18.59	15,410	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTRA) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Natera (NTRA) Competitors

NTRA vs. AMGN, GILD, VRTX, REGN, and MRNA

How does Natera compare to Amgen?

Summary

How does Natera compare to Gilead Sciences?

Summary

How does Natera compare to Vertex Pharmaceuticals?

Summary

How does Natera compare to Regeneron Pharmaceuticals?

Summary

How does Natera compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRA vs. The Competition

Natera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Natera (NTRA) Competitors

NTRA vs. AMGN, GILD, VRTX, REGN, and MRNA

How does Natera compare to Amgen?

Which has stronger valuation & earnings, AMGN or NTRA?

Which has more volatility and risk, AMGN or NTRA?

Do analysts rate AMGN or NTRA?

Does the media refer more to AMGN or NTRA?

Do institutionals and insiders hold more shares of AMGN or NTRA?

Is AMGN or NTRA more profitable?

Summary

How does Natera compare to Gilead Sciences?

Does the media favor NTRA or GILD?

Which has more risk & volatility, NTRA or GILD?

Do analysts recommend NTRA or GILD?

Is NTRA or GILD more profitable?

Which has preferable earnings and valuation, NTRA or GILD?

Do insiders & institutionals believe in NTRA or GILD?

Summary

How does Natera compare to Vertex Pharmaceuticals?

Does the media prefer VRTX or NTRA?

Do insiders and institutionals believe in VRTX or NTRA?

Which has preferable earnings & valuation, VRTX or NTRA?

Is VRTX or NTRA more profitable?

Which has more volatility and risk, VRTX or NTRA?

Do analysts rate VRTX or NTRA?

Summary

How does Natera compare to Regeneron Pharmaceuticals?

Is REGN or NTRA more profitable?

Which has preferable valuation and earnings, REGN or NTRA?

Does the media refer more to REGN or NTRA?

Which has more risk and volatility, REGN or NTRA?

Do institutionals and insiders believe in REGN or NTRA?

Do analysts rate REGN or NTRA?

Summary

How does Natera compare to Moderna?

Do insiders & institutionals believe in MRNA or NTRA?

Is MRNA or NTRA more profitable?

Which has more risk & volatility, MRNA or NTRA?

Which has better earnings and valuation, MRNA or NTRA?

Does the media refer more to MRNA or NTRA?

Do analysts recommend MRNA or NTRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRA vs. The Competition

Natera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools